Skip to main content
. 2020 May 1;2020(5):CD008649. doi: 10.1002/14651858.CD008649.pub4

2.3. Analysis.

2.3

Comparison 2: Mannitol versus control ‐ cross‐over studies of individuals with cystic fibrosis, Outcome 3: FEV1 % predicted (absolute change from baseline ‐ subgroup analysis by dornase alfa use